Mobilization and Collection of HSC-Reference-Cited by-同舟云学术

Mobilization and Collection of HSC

Published:2024 Issue: Volume: Page:151-157
ISSN:
Container-title:The EBMT Handbook
language:en
Short-container-title:

Author:

Worel Nina,Bilgin Yavuz M.,Wuchter Patrick

Abstract

AbstractThe intravenous infusion of patient’s own HSC (autologous SCT) to restore BM damage is the basic principle of high-dose chemotherapy, since otherwise the patient would expect long-lasting aplasia with life-threatening infections. Therefore, a sufficient collection of HSC before application of high-dose therapy is mandatory. Since HSC expresses CD34 on their surface, the number of CD34+ cells in the transplant material is considered as an indicator of the HSC content.The aim of infusion of HSC from a donor (allogeneic SCT) is to restore BM damage and to treat the patient’s disease. It represents a permanent cellular immunotherapy by adding a graft versus tumor effect in malignant diseases.

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-031-44080-9_16

Reference34 articles.

1. Abrahamsen JF, Stamnesfet S, Liseth K, et al. Large-volume leukapheresis yields more viable CD34+ cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34+ cells. Transfusion. 2005;45:248–53.

2. Baertsch MA, Schlenzka J, Lisenko K, et al. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE. Eur J Haematol. 2017;99(1):42–50.

3. Bilgin YM. Use of plerixafor for stem cell mobilization in the setting of autologous and allogeneic stem cell transplantations: an update. J Blood Med. 2021;2:403–12.

4. Bilgin YM, Visser O, Beckers EA, et al. Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor. Transfusion. 2015;55:1021–7.

5. Cheng J, Schmitt M, Wuchter P, et al. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. Transfusion. 2015;55:275–83.